465 related articles for article (PubMed ID: 31256161)
1. Why the 20% + 2 Tryptase Formula Is a Diagnostic Gold Standard for Severe Systemic Mast Cell Activation and Mast Cell Activation Syndrome.
Valent P; Bonadonna P; Hartmann K; Broesby-Olsen S; Brockow K; Butterfield JH; Triggiani M; Lyons JJ; Oude Elberink JNG; Arock M; Metcalfe DD; Akin C
Int Arch Allergy Immunol; 2019; 180(1):44-51. PubMed ID: 31256161
[TBL] [Abstract][Full Text] [Related]
2. Reversible Elevation of Tryptase Over the Individual's Baseline: Why is It the Best Biomarker for Severe Systemic Mast Cell Activation and MCAS?
Valent P; Akin C; Arock M
Curr Allergy Asthma Rep; 2024 Mar; 24(3):133-141. PubMed ID: 38308674
[TBL] [Abstract][Full Text] [Related]
3. Hymenoptera Allergy and Mast Cell Activation Syndromes.
Bonadonna P; Bonifacio M; Lombardo C; Zanotti R
Curr Allergy Asthma Rep; 2016 Jan; 16(1):5. PubMed ID: 26714690
[TBL] [Abstract][Full Text] [Related]
4. Mast cell activation syndrome: improved identification by combined determinations of serum tryptase and 24-hour urine 11β-prostaglandin2α.
Ravi A; Butterfield J; Weiler CR
J Allergy Clin Immunol Pract; 2014; 2(6):775-8. PubMed ID: 25439370
[TBL] [Abstract][Full Text] [Related]
5. Diagnostic value of tryptase in anaphylaxis and mastocytosis.
Schwartz LB
Immunol Allergy Clin North Am; 2006 Aug; 26(3):451-63. PubMed ID: 16931288
[TBL] [Abstract][Full Text] [Related]
6. A Challenge for Allergologist: Application of Allergy Diagnostic Methods in Mast Cell Disorders.
Romantowski J; Górska A; Niedoszytko M; Gulen T; Gruchała-Niedoszytko M; Nedoszytko B; Lange M; Brockow K; Arock M; Akin C; Valent P
Int J Mol Sci; 2021 Feb; 22(3):. PubMed ID: 33535634
[TBL] [Abstract][Full Text] [Related]
7. Determination of plasma heparin level improves identification of systemic mast cell activation disease.
Vysniauskaite M; Hertfelder HJ; Oldenburg J; Dreßen P; Brettner S; Homann J; Molderings GJ
PLoS One; 2015; 10(4):e0124912. PubMed ID: 25909362
[TBL] [Abstract][Full Text] [Related]
8. Mast Cell Activation Syndrome.
Frieri M
Clin Rev Allergy Immunol; 2018 Jun; 54(3):353-365. PubMed ID: 25944644
[TBL] [Abstract][Full Text] [Related]
9. Clinical impact of the TPSAB1 genotype in mast cell diseases: A REMA study in a cohort of 959 individuals.
González-de-Olano D; Navarro-Navarro P; Muñoz-González JI; Sánchez-Muñoz L; Henriques A; de-Andrés-Martín A; Peralta-Arjonilla D; Mayado A; Jara-Acevedo M; García-Montero AC; Orfao A; Álvarez-Twose I
Allergy; 2024 Mar; 79(3):711-723. PubMed ID: 37818990
[TBL] [Abstract][Full Text] [Related]
10. Low Prevalence of Idiopathic Mast Cell Activation Syndrome Among 703 Patients With Suspected Mast Cell Disorders.
Zaghmout T; Maclachlan L; Bedi N; Gülen T
J Allergy Clin Immunol Pract; 2024 Mar; 12(3):753-761. PubMed ID: 38056692
[TBL] [Abstract][Full Text] [Related]
11. Mast cell activation syndromes presenting as anaphylaxis.
Akin C
Immunol Allergy Clin North Am; 2015 May; 35(2):277-85. PubMed ID: 25841551
[TBL] [Abstract][Full Text] [Related]
12. Mastocytosis and related entities: a practical roadmap.
Beyens M; Elst J; van der Poorten ML; Van Gasse A; Toscano A; Verlinden A; Vermeulen K; Maes MB; Oude Elberink JNGH; Ebo D; Sabato V
Acta Clin Belg; 2023 Aug; 78(4):325-335. PubMed ID: 36259506
[TBL] [Abstract][Full Text] [Related]
13. Incorporating Tryptase Genotyping Into the Workup and Diagnosis of Mast Cell Diseases and Reactions.
Lyons JJ; Greiner G; Hoermann G; Metcalfe DD
J Allergy Clin Immunol Pract; 2022 Aug; 10(8):1964-1973. PubMed ID: 35597543
[TBL] [Abstract][Full Text] [Related]
14. Clonal mast cell disorders in patients with severe Hymenoptera venom allergy and normal serum tryptase levels.
Zanotti R; Lombardo C; Passalacqua G; Caimmi C; Bonifacio M; De Matteis G; Perbellini O; Rossini M; Schena D; Busa M; Marcotulli MC; Bilò MB; Franchini M; Marchi G; Simioni L; Bonadonna P
J Allergy Clin Immunol; 2015 Jul; 136(1):135-9. PubMed ID: 25605272
[TBL] [Abstract][Full Text] [Related]
15. The alpha form of human tryptase is the predominant type present in blood at baseline in normal subjects and is elevated in those with systemic mastocytosis.
Schwartz LB; Sakai K; Bradford TR; Ren S; Zweiman B; Worobec AS; Metcalfe DD
J Clin Invest; 1995 Dec; 96(6):2702-10. PubMed ID: 8675637
[TBL] [Abstract][Full Text] [Related]
16. Venom immunotherapy in patients with mastocytosis and hymenoptera venom anaphylaxis.
González-de-Olano D; Alvarez-Twose I; Vega A; Orfao A; Escribano L
Immunotherapy; 2011 May; 3(5):637-51. PubMed ID: 21554093
[TBL] [Abstract][Full Text] [Related]
17. Human mast cell tryptase in biology and medicine.
Vitte J
Mol Immunol; 2015 Jan; 63(1):18-24. PubMed ID: 24793463
[TBL] [Abstract][Full Text] [Related]
18. Expanding spectrum of mast cell activation disorders: monoclonal and idiopathic mast cell activation syndromes.
Picard M; Giavina-Bianchi P; Mezzano V; Castells M
Clin Ther; 2013 May; 35(5):548-62. PubMed ID: 23642289
[TBL] [Abstract][Full Text] [Related]
19. Validation of international consensus equation for acute serum total tryptase in mast cell activation: A perioperative perspective.
Baretto RL; Beck S; Heslegrave J; Melchior C; Mohamed O; Ekbote A; Huissoon AP; Krishna MT
Allergy; 2017 Dec; 72(12):2031-2034. PubMed ID: 28609557
[TBL] [Abstract][Full Text] [Related]
20. Tryptase levels as an indicator of mast-cell activation in systemic anaphylaxis and mastocytosis.
Schwartz LB; Metcalfe DD; Miller JS; Earl H; Sullivan T
N Engl J Med; 1987 Jun; 316(26):1622-6. PubMed ID: 3295549
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
